0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: Trial-level meta-analysis to investigate differences in immune-related adverse event (irAE) profiles between anti-PD-1/PD-L1 antibodies. Materials & methods: Data analyzed from 8730 patients treated with anti-PD-1/PD-L1 monotherapy. Incidence and odds ratios (ORs) were calculated for irAEs overall, selected individual irAEs for individual agents and pooled estimates for anti-PD-1 or anti-PD-L1 antibodies. Results: For anti-PD-L1 versus anti-PD-1 antibodies, we observed a lower risk of any-grade rash, elevated alanine aminotransferase, colitis, grade ≥3 colitis, hypothyroidism and rash. For individual agents, we observed reduced risks of overall any-grade irAEs for atezolizumab versus pembrolizumab and grade ≥3 irAEs for avelumab versus pembrolizumab. Conclusion: irAE risk may vary between anti-PD-1 and anti-PD-L1 antibodies; however, findings are hypothesis-generating.

          Related collections

          Author and article information

          Journal
          Future Oncol
          Future oncology (London, England)
          Future Medicine Ltd
          1744-8301
          1479-6694
          Jul 2021
          : 17
          : 19
          Affiliations
          [1 ] Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA.
          [2 ] Department of Medicine, Division of Medical Oncology, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 1144 Eastlake Ave, E. LG-465, Seattle, WA 98109, USA.
          [3 ] PharmStats, Missouri City, TX 77459, USA.
          [4 ] EMD Serono, Inc, Rockland, MA 01821, USA; an affiliate of Merck KGaA, Darmstadt, Germany.
          [5 ] Current affiliation: Constellation Pharmaceuticals, Inc, 215 First St, Suite 200, Cambridge, MA 02142, USA.
          Article
          10.2217/fon-2020-1222
          33783228
          988715a6-a35f-4f3f-808c-86872add9226
          History

          anti-PD-1,anti-PD-L1,immune checkpoint inhibitor,immune-related adverse events,meta-analysis

          Comments

          Comment on this article